Creating a new generation of small molecule serine protease inhibitors

News

KalVista Pharmaceuticals Raises $33 Million to Advance Development of Novel Plasma Kallikrein Inhibitors in Diabetic Macular Edema and Hereditary Angioedema

22 July 2015 Read more...

KalVista announces start of clinical development for novel treatment for diabetic macular edema

20 August 2014 Read more...

KalVista brings expertise to new European consortium focused on the discovery and development of novel eye therapeutics

25 September 2013 Read more...

KalVista wins £2.4m Biomedical Catalyst grant to further develop oral plasma kallikrein inhibitors as a treatment for diabetic macular edema

26 November 2012 Read more...

Registered Office: Building 227, Tetricus Science Park, Porton Down, SP4 0JQ, United Kingdom Registered in England. Registered No: 07543947